Nanoliposomal irinotecan (Nal-IRI)-based chemotherapy after irinotecan -based chemotherapy in patients with pancreas cancer
Nanoliposomal irinotecan (Nal-IRI) is a preferred second-line treatment for metastatic pancreas cancer. It is unclear, however, whether patients who had received irinotecan derive benefit. Medical records of metastatic pancreas cancer patients who had received irinotecan and then Nal-IRI were review...
Gespeichert in:
| Veröffentlicht in: | Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] 2021-03, Vol.21 (2), p.379-383 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 383 |
|---|---|
| container_issue | 2 |
| container_start_page | 379 |
| container_title | Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.] |
| container_volume | 21 |
| creator | Smith, Caleb J. Bekaii-Saab, Tanios S. Cook, Kathryn D. Eiring, Rachel A. Halfdanarson, Thorvardur R. Hanna, Mina Jin, Zhaohui Jochum, Jacob A. Ma, Wen Wee Mitchell, Jessica L. Pitot, Henry C. Jatoi, Aminah |
| description | Nanoliposomal irinotecan (Nal-IRI) is a preferred second-line treatment for metastatic pancreas cancer. It is unclear, however, whether patients who had received irinotecan derive benefit.
Medical records of metastatic pancreas cancer patients who had received irinotecan and then Nal-IRI were reviewed. The primary endpoint was overall survival after the initiation of Nal-IRI (an a priori threshold of >4 months defined success); adverse events and quotes from the medical record on decision-making were also recorded.
Sixty four patients met eligibility criteria with a median age of 65 years (range: 36, 80 years). The median overall survival from initiation of Nal-IRI was 5.1 months (95% confidence interval (CI): 4.3, 5.6 months). An exploratory comparison, based on no cancer progression with irinotecan versus progression, showed improved survival with Nal-IRI in the former group: 6.1 months (95% CI: 5.1, 9.3 months) versus 4.3 months (95% CI: 2.3, 4.8 months); p = 0.0006. Nal-IRI adverse events occurred as expected. Qualitative data illustrate several themes, including “limited treatment options,” which appeared to drive the decision to prescribe Nal-IRI.
Nal-IRI might be considered in pancreas cancer patients who had received irinotecan, particularly in the absence of disease progression with the latter. |
| doi_str_mv | 10.1016/j.pan.2020.10.042 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2479418576</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1424390320307936</els_id><sourcerecordid>2500364401</sourcerecordid><originalsourceid>FETCH-LOGICAL-c381t-c638a174c1308bdfd946fdd7dd3d9f2bbd7d1eb413afa861bf01a6767ae3fb663</originalsourceid><addsrcrecordid>eNp9kU9rFTEUxYMotlY_gBsZcNMu5pmbpJkZXEmx-qBUEF2HTHLDy2MmGZM8pfjlzfBqERFX9w-_c0juIeQl0A1QkG_2m0WHDaNsnTdUsEfkFAQTLR8AHj_0lJ-QZznvKWUMYHhKTjgXsueDOCU_b3WIk19ijrOeGp98iAWNDs35rZ7a7eftRTvqjLYxO5xj2WHSy12jXcH0J_0vyIdm0cVjKLn54cuuTsEk1LmpCoPpOXni9JTxxX09I1-v33-5-tjefPqwvXp30xreQ2mN5L2GThjgtB-ts4OQztrOWm4Hx8axtoCjAK6d7iWMjoKWnew0cjdKyc_I-dF3SfHbAXNRs88Gp0kHjIesmOgGAf1lt6Kv_0L38ZBCfZ1il5RyKQSFSsGRMinmnNCpJflZpzsFVK3JqL2qf1VrMuuqJlM1r-6dD-OM9kHxO4oKvD0CWE_x3WNS2dTbGbQ-oSnKRv8f-1-i3aAn</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2500364401</pqid></control><display><type>article</type><title>Nanoliposomal irinotecan (Nal-IRI)-based chemotherapy after irinotecan -based chemotherapy in patients with pancreas cancer</title><source>Alma/SFX Local Collection</source><creator>Smith, Caleb J. ; Bekaii-Saab, Tanios S. ; Cook, Kathryn D. ; Eiring, Rachel A. ; Halfdanarson, Thorvardur R. ; Hanna, Mina ; Jin, Zhaohui ; Jochum, Jacob A. ; Ma, Wen Wee ; Mitchell, Jessica L. ; Pitot, Henry C. ; Jatoi, Aminah</creator><creatorcontrib>Smith, Caleb J. ; Bekaii-Saab, Tanios S. ; Cook, Kathryn D. ; Eiring, Rachel A. ; Halfdanarson, Thorvardur R. ; Hanna, Mina ; Jin, Zhaohui ; Jochum, Jacob A. ; Ma, Wen Wee ; Mitchell, Jessica L. ; Pitot, Henry C. ; Jatoi, Aminah</creatorcontrib><description>Nanoliposomal irinotecan (Nal-IRI) is a preferred second-line treatment for metastatic pancreas cancer. It is unclear, however, whether patients who had received irinotecan derive benefit.
Medical records of metastatic pancreas cancer patients who had received irinotecan and then Nal-IRI were reviewed. The primary endpoint was overall survival after the initiation of Nal-IRI (an a priori threshold of >4 months defined success); adverse events and quotes from the medical record on decision-making were also recorded.
Sixty four patients met eligibility criteria with a median age of 65 years (range: 36, 80 years). The median overall survival from initiation of Nal-IRI was 5.1 months (95% confidence interval (CI): 4.3, 5.6 months). An exploratory comparison, based on no cancer progression with irinotecan versus progression, showed improved survival with Nal-IRI in the former group: 6.1 months (95% CI: 5.1, 9.3 months) versus 4.3 months (95% CI: 2.3, 4.8 months); p = 0.0006. Nal-IRI adverse events occurred as expected. Qualitative data illustrate several themes, including “limited treatment options,” which appeared to drive the decision to prescribe Nal-IRI.
Nal-IRI might be considered in pancreas cancer patients who had received irinotecan, particularly in the absence of disease progression with the latter.</description><identifier>ISSN: 1424-3903</identifier><identifier>EISSN: 1424-3911</identifier><identifier>DOI: 10.1016/j.pan.2020.10.042</identifier><identifier>PMID: 33468394</identifier><language>eng</language><publisher>Switzerland: Elsevier B.V</publisher><subject>Cancer therapies ; Chemotherapy ; Confidence intervals ; Decision making ; Guidelines ; Irinotecan ; Liposomal ; Medical records ; Metastases ; Metastasis ; Pancreas ; Pancreas cancer ; Pancreatic cancer ; Patients ; Survival</subject><ispartof>Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 2021-03, Vol.21 (2), p.379-383</ispartof><rights>2020</rights><rights>Copyright © 2020. Published by Elsevier B.V.</rights><rights>Copyright Elsevier Limited Mar 2021</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c381t-c638a174c1308bdfd946fdd7dd3d9f2bbd7d1eb413afa861bf01a6767ae3fb663</citedby><cites>FETCH-LOGICAL-c381t-c638a174c1308bdfd946fdd7dd3d9f2bbd7d1eb413afa861bf01a6767ae3fb663</cites><orcidid>0000-0001-8460-1257 ; 0000-0002-4490-9377 ; 0000-0002-1081-189X ; 0000-0001-5899-4034 ; 0000-0003-1974-0175 ; 0000-0001-7844-5833 ; 0000-0002-7438-6626</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27922,27923</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/33468394$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Smith, Caleb J.</creatorcontrib><creatorcontrib>Bekaii-Saab, Tanios S.</creatorcontrib><creatorcontrib>Cook, Kathryn D.</creatorcontrib><creatorcontrib>Eiring, Rachel A.</creatorcontrib><creatorcontrib>Halfdanarson, Thorvardur R.</creatorcontrib><creatorcontrib>Hanna, Mina</creatorcontrib><creatorcontrib>Jin, Zhaohui</creatorcontrib><creatorcontrib>Jochum, Jacob A.</creatorcontrib><creatorcontrib>Ma, Wen Wee</creatorcontrib><creatorcontrib>Mitchell, Jessica L.</creatorcontrib><creatorcontrib>Pitot, Henry C.</creatorcontrib><creatorcontrib>Jatoi, Aminah</creatorcontrib><title>Nanoliposomal irinotecan (Nal-IRI)-based chemotherapy after irinotecan -based chemotherapy in patients with pancreas cancer</title><title>Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]</title><addtitle>Pancreatology</addtitle><description>Nanoliposomal irinotecan (Nal-IRI) is a preferred second-line treatment for metastatic pancreas cancer. It is unclear, however, whether patients who had received irinotecan derive benefit.
Medical records of metastatic pancreas cancer patients who had received irinotecan and then Nal-IRI were reviewed. The primary endpoint was overall survival after the initiation of Nal-IRI (an a priori threshold of >4 months defined success); adverse events and quotes from the medical record on decision-making were also recorded.
Sixty four patients met eligibility criteria with a median age of 65 years (range: 36, 80 years). The median overall survival from initiation of Nal-IRI was 5.1 months (95% confidence interval (CI): 4.3, 5.6 months). An exploratory comparison, based on no cancer progression with irinotecan versus progression, showed improved survival with Nal-IRI in the former group: 6.1 months (95% CI: 5.1, 9.3 months) versus 4.3 months (95% CI: 2.3, 4.8 months); p = 0.0006. Nal-IRI adverse events occurred as expected. Qualitative data illustrate several themes, including “limited treatment options,” which appeared to drive the decision to prescribe Nal-IRI.
Nal-IRI might be considered in pancreas cancer patients who had received irinotecan, particularly in the absence of disease progression with the latter.</description><subject>Cancer therapies</subject><subject>Chemotherapy</subject><subject>Confidence intervals</subject><subject>Decision making</subject><subject>Guidelines</subject><subject>Irinotecan</subject><subject>Liposomal</subject><subject>Medical records</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Pancreas</subject><subject>Pancreas cancer</subject><subject>Pancreatic cancer</subject><subject>Patients</subject><subject>Survival</subject><issn>1424-3903</issn><issn>1424-3911</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2021</creationdate><recordtype>article</recordtype><recordid>eNp9kU9rFTEUxYMotlY_gBsZcNMu5pmbpJkZXEmx-qBUEF2HTHLDy2MmGZM8pfjlzfBqERFX9w-_c0juIeQl0A1QkG_2m0WHDaNsnTdUsEfkFAQTLR8AHj_0lJ-QZznvKWUMYHhKTjgXsueDOCU_b3WIk19ijrOeGp98iAWNDs35rZ7a7eftRTvqjLYxO5xj2WHSy12jXcH0J_0vyIdm0cVjKLn54cuuTsEk1LmpCoPpOXni9JTxxX09I1-v33-5-tjefPqwvXp30xreQ2mN5L2GThjgtB-ts4OQztrOWm4Hx8axtoCjAK6d7iWMjoKWnew0cjdKyc_I-dF3SfHbAXNRs88Gp0kHjIesmOgGAf1lt6Kv_0L38ZBCfZ1il5RyKQSFSsGRMinmnNCpJflZpzsFVK3JqL2qf1VrMuuqJlM1r-6dD-OM9kHxO4oKvD0CWE_x3WNS2dTbGbQ-oSnKRv8f-1-i3aAn</recordid><startdate>202103</startdate><enddate>202103</enddate><creator>Smith, Caleb J.</creator><creator>Bekaii-Saab, Tanios S.</creator><creator>Cook, Kathryn D.</creator><creator>Eiring, Rachel A.</creator><creator>Halfdanarson, Thorvardur R.</creator><creator>Hanna, Mina</creator><creator>Jin, Zhaohui</creator><creator>Jochum, Jacob A.</creator><creator>Ma, Wen Wee</creator><creator>Mitchell, Jessica L.</creator><creator>Pitot, Henry C.</creator><creator>Jatoi, Aminah</creator><general>Elsevier B.V</general><general>Elsevier Limited</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-8460-1257</orcidid><orcidid>https://orcid.org/0000-0002-4490-9377</orcidid><orcidid>https://orcid.org/0000-0002-1081-189X</orcidid><orcidid>https://orcid.org/0000-0001-5899-4034</orcidid><orcidid>https://orcid.org/0000-0003-1974-0175</orcidid><orcidid>https://orcid.org/0000-0001-7844-5833</orcidid><orcidid>https://orcid.org/0000-0002-7438-6626</orcidid></search><sort><creationdate>202103</creationdate><title>Nanoliposomal irinotecan (Nal-IRI)-based chemotherapy after irinotecan -based chemotherapy in patients with pancreas cancer</title><author>Smith, Caleb J. ; Bekaii-Saab, Tanios S. ; Cook, Kathryn D. ; Eiring, Rachel A. ; Halfdanarson, Thorvardur R. ; Hanna, Mina ; Jin, Zhaohui ; Jochum, Jacob A. ; Ma, Wen Wee ; Mitchell, Jessica L. ; Pitot, Henry C. ; Jatoi, Aminah</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c381t-c638a174c1308bdfd946fdd7dd3d9f2bbd7d1eb413afa861bf01a6767ae3fb663</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2021</creationdate><topic>Cancer therapies</topic><topic>Chemotherapy</topic><topic>Confidence intervals</topic><topic>Decision making</topic><topic>Guidelines</topic><topic>Irinotecan</topic><topic>Liposomal</topic><topic>Medical records</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Pancreas</topic><topic>Pancreas cancer</topic><topic>Pancreatic cancer</topic><topic>Patients</topic><topic>Survival</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Smith, Caleb J.</creatorcontrib><creatorcontrib>Bekaii-Saab, Tanios S.</creatorcontrib><creatorcontrib>Cook, Kathryn D.</creatorcontrib><creatorcontrib>Eiring, Rachel A.</creatorcontrib><creatorcontrib>Halfdanarson, Thorvardur R.</creatorcontrib><creatorcontrib>Hanna, Mina</creatorcontrib><creatorcontrib>Jin, Zhaohui</creatorcontrib><creatorcontrib>Jochum, Jacob A.</creatorcontrib><creatorcontrib>Ma, Wen Wee</creatorcontrib><creatorcontrib>Mitchell, Jessica L.</creatorcontrib><creatorcontrib>Pitot, Henry C.</creatorcontrib><creatorcontrib>Jatoi, Aminah</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Smith, Caleb J.</au><au>Bekaii-Saab, Tanios S.</au><au>Cook, Kathryn D.</au><au>Eiring, Rachel A.</au><au>Halfdanarson, Thorvardur R.</au><au>Hanna, Mina</au><au>Jin, Zhaohui</au><au>Jochum, Jacob A.</au><au>Ma, Wen Wee</au><au>Mitchell, Jessica L.</au><au>Pitot, Henry C.</au><au>Jatoi, Aminah</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Nanoliposomal irinotecan (Nal-IRI)-based chemotherapy after irinotecan -based chemotherapy in patients with pancreas cancer</atitle><jtitle>Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.]</jtitle><addtitle>Pancreatology</addtitle><date>2021-03</date><risdate>2021</risdate><volume>21</volume><issue>2</issue><spage>379</spage><epage>383</epage><pages>379-383</pages><issn>1424-3903</issn><eissn>1424-3911</eissn><abstract>Nanoliposomal irinotecan (Nal-IRI) is a preferred second-line treatment for metastatic pancreas cancer. It is unclear, however, whether patients who had received irinotecan derive benefit.
Medical records of metastatic pancreas cancer patients who had received irinotecan and then Nal-IRI were reviewed. The primary endpoint was overall survival after the initiation of Nal-IRI (an a priori threshold of >4 months defined success); adverse events and quotes from the medical record on decision-making were also recorded.
Sixty four patients met eligibility criteria with a median age of 65 years (range: 36, 80 years). The median overall survival from initiation of Nal-IRI was 5.1 months (95% confidence interval (CI): 4.3, 5.6 months). An exploratory comparison, based on no cancer progression with irinotecan versus progression, showed improved survival with Nal-IRI in the former group: 6.1 months (95% CI: 5.1, 9.3 months) versus 4.3 months (95% CI: 2.3, 4.8 months); p = 0.0006. Nal-IRI adverse events occurred as expected. Qualitative data illustrate several themes, including “limited treatment options,” which appeared to drive the decision to prescribe Nal-IRI.
Nal-IRI might be considered in pancreas cancer patients who had received irinotecan, particularly in the absence of disease progression with the latter.</abstract><cop>Switzerland</cop><pub>Elsevier B.V</pub><pmid>33468394</pmid><doi>10.1016/j.pan.2020.10.042</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0001-8460-1257</orcidid><orcidid>https://orcid.org/0000-0002-4490-9377</orcidid><orcidid>https://orcid.org/0000-0002-1081-189X</orcidid><orcidid>https://orcid.org/0000-0001-5899-4034</orcidid><orcidid>https://orcid.org/0000-0003-1974-0175</orcidid><orcidid>https://orcid.org/0000-0001-7844-5833</orcidid><orcidid>https://orcid.org/0000-0002-7438-6626</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1424-3903 |
| ispartof | Pancreatology : official journal of the International Association of Pancreatology (IAP) ... [et al.], 2021-03, Vol.21 (2), p.379-383 |
| issn | 1424-3903 1424-3911 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2479418576 |
| source | Alma/SFX Local Collection |
| subjects | Cancer therapies Chemotherapy Confidence intervals Decision making Guidelines Irinotecan Liposomal Medical records Metastases Metastasis Pancreas Pancreas cancer Pancreatic cancer Patients Survival |
| title | Nanoliposomal irinotecan (Nal-IRI)-based chemotherapy after irinotecan -based chemotherapy in patients with pancreas cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-14T15%3A50%3A29IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Nanoliposomal%20irinotecan%20(Nal-IRI)-based%20chemotherapy%20after%20irinotecan%20-based%20chemotherapy%20in%20patients%20with%20pancreas%20cancer&rft.jtitle=Pancreatology%20:%20official%20journal%20of%20the%20International%20Association%20of%20Pancreatology%20(IAP)%20...%20%5Bet%20al.%5D&rft.au=Smith,%20Caleb%20J.&rft.date=2021-03&rft.volume=21&rft.issue=2&rft.spage=379&rft.epage=383&rft.pages=379-383&rft.issn=1424-3903&rft.eissn=1424-3911&rft_id=info:doi/10.1016/j.pan.2020.10.042&rft_dat=%3Cproquest_cross%3E2500364401%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2500364401&rft_id=info:pmid/33468394&rft_els_id=S1424390320307936&rfr_iscdi=true |